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Abstract  
 
The two novel prodrugs of amoxicillin and cephalexin were synthesized to improve the 
stability and bitter taste of their parent drugs. The in vitro susceptibility for both prodrugs 
was determined against Escherichia coli, staphylococcus epidermidis, staphylococcus 
aureus, Klebsiella pneumonia, streptococcus group A, streptococcus group B, and 
compared to that of their parents. 
The results revealed that both novel prodrugs have antibacterial activity on most bacterial 
strains with about the same potency as their parent drugs, In addition, Klebsiella 
pneumonia, and staphylococcus epidermidis showed resistance to both amoxicillin drug 
and its prodrug. Since klebsiella is gram negative bacteria and staphylococcus 
epidermidise is beta lactamase positive . 
It is worth noting that those two novel prodrugs are among a small number of prodrugs 
that have activity themselves before undergoing conversion via enzymatic or chemical 
processes to their corresponding parent drugs. The novel prodrugs exhibit their 
antibacterial activity against different types of bacterial strains due to the presence of beta 
lactam ring in their structures.  
In addition, it is expected that the novel two prodrugs will be much more stable in 
aqueous media than their corresponding parent drugs due to the fact that the sensitive 
amine group exists in the parent drugs was replaced with a more stable group, amide 
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Chapter One 
1. Introduction 
1.1.1 Historical Background 
 
Infectious diseases are as old as lifetime itself. They account for a major 
proportion of overall diseases. Infectious diseases caused by microorganisms were 
plaguing mankind from ancient days until the half of 19
th
 century. Accordingly 
chemotherapy endeavor to cure these infectious diseases. In 1910, Ehrlich synthesized 
salvarsan for treatment of syphilis to become the first antimicrobial drug in the world. In 
1929 Fleming observed that bacterial growth was inhibited in presence of Penicillium 
notatum. This observation makes penicillin the first broad antibiotic used in 1940s and 
led to its use during World War II. In 1935 Domagk  developed sulfonamides [2], and the 
second synthetic antibiotics,  which were discovered  in 1962 were quinolones (e.g. 
Ciprofloxacin). Then it was followed in 1979 by the discovery of oxazolidinones [3]. 
Figure 1.1 shows the timeline discovery of antibiotics with natural and synthetic origins. 
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Figure (1.1): Timeline of discovery novel classes of antibiotics [3].  
 
 
1.1.1 Discovery of Penicillin 
 
John. Burdon  Sanderson and William Robert  independently noted that bacterial growth 
was prevented in the presence of fungi [4]. The same observation was noted by John 
Tyndall in 1876 upon surmising the antagonism of bacterial growth due to the low 
oxygen level, which presumably was consumed by fungi. 
The first in vitro work was done by Cornil and Babes. Both scientists assessed the 
microbial inhibition and antagonism. They explained this observation as a substance 
produced by one microorganism that may serve as an antagonist for the growth of another 
[4, 5]. 
In 1887 Garre observed that the staphylococcus pyogens growth was inhibited in the 
presence of Bacillus fluorescence. Another notable observation which was noted by 
Ernest Duschesne in 1897 is the antagonism between Penicillium and Escherichia 
bacteria. In 1941, Selman Waksman named these observations as antibiosis [4]. The true 
story began in 1928 by Alexander Fleming, a Scottish bacteriologist, who became 
Pencillin 
1929-1941 
Tetracyclin
e1949 
Glycopeptidase 
vancomycin 1956-1976 
1956 
Quinolones19
60-1962 
10 Beta lactam 
carbapenems 
1976-1985 
Oxazolidones. 
Linezolid 1997-
2000 
Daptomycin 2003 
Aminoglycosi
de 
Streptomycin 
1946 -1950 
 
Phenylpropanoids 
chloramphenicol 
1946 
Chloramphenicol 
C 
Macrolide 
erythromycin1962 
1930       1940          1950      1960      1970          1980     1990    2000 
 
2
nd
cephalosporin 
1962 
 3 
 
Professor of bacteriology at St. Mary’s hospital medical school in London. In the summer 
of 1928 before leaving London to his home in Suffolk he accumulated all his 
staphylococcus aureus culture plates on one edge of his laboratory board. When he 
returned he observed that there was a colony of mold growing on one side and the 
Staphylococcus aureus around this area disappeared.  However, the Staphylococcus 
aureus away from the mold still had normal growth (Figure1.2). 
Fleming was interested in this observation and he sub-cultured the mold and studied it. 
The culture of the mold was in nutrient broth and was for a period of eight days at room 
temperature. Fleming noticed that there was complete inhibition of growth of many 
bacteria. This fluid was first called mold juice; and later on the 7
th
 of march 1929, 
Fleming named the active substance penicillin [6, 7]. 
Fleming 1929’s paper flagged the way to an important future research. First he pictured 
the mold and its growth temperatures, and observed that it has a rapid production at 20 
o
C. Then he studied other types of molds to check if their antibacterial activity and to 
confirm the unique nature of the strain he discovered. 
To identify and test the antibacterial action of this strain of mold, Fleming made a cut in 
the agar plate where he saturated this cut with the mold’s filtrate. Then when the ditch 
became solid, seven different microorganisms were applied to characterize the growth 
and inhibition mode for each. In addition, he tested the inhibition incidence in mm for 
different organisms and monitored the inhibitory changes as a result of dilutions of the 
filtrate. The procedures used by Fleming are equivalent to MIC and still in use up to these 
days. 
Fleming had a background and expertise in immunological research at St. Mary’s 
laboratory.  This background helped him determine how to deal with foreign substance 
with host cell; he injected 20 mL of broth containing penicillin into rabbits and in mice 
which had no toxic effect as well [8]. Moreover, Fleming who already had experience in 
antiseptics, noted that his filtrate has an efficient effect when was applied on infected 
surfaces. During this time period Clutterbuck, Lovell and Raistrich extracted the active 
compound from the mold. They found that a pure compound could be separated by ether 
and watery acidic medium extractions. Upon evaporating the ether they recognized that 
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the activity of the compound was diminished which led them to conclude that the active 
ingredient (penicillin) is unstable compound in acidic aqueous medium [7]. 
 
 
 
 
 
 
 
 
Figure (1.2): Fleming’s original plate. 
 
 
 
1.1.1 β- lactam Antibiotics Structure 
 
Structurally, beta-lactam antibiotic molecules contain beta-lactam nucleus (6-amino 
pencillinc acid or 7-amino cephalosporinic acid), which provide the key for synthesis and 
modification (Figure1.3 a-b). 
 
 
Bacterial Colony 
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Figure (1.3a): 6-aminopenicillanic acid      
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Figure (1.3b):  7-aminocephalosporanic acid  
 
This important nucleus provides a key for novel beta-lactam agents to be 
synthesized by linking a unique side chain to 6-APA. Early work by J.C. Sheehan 
produced penicillin V by acylation of synthesized 6-APA. Thereafter, in 1960 methicillin 
was approved in the United States and became the first semisynthetic penicillin which is 
stable to enzymatic degradation, especially to penicillinase enzyme. 
In addition, in 1967 carbenicillin was produced as semisynthetic compound by adding a 
carboxyl group instead of the amino group of ampicillin. Natural source did not stop here; 
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Abraham and Newton isolated a new family of beta-lactam antibiotics from 
Cephalosporium acremonium called cephalosporin C which contain 7-ACA nucleus 
instead of 6-APA in penicillin [5]. 
Chemical modification on beta-lactam antibiotics produced many semisynthetic 
compounds. For example, various salts or esters of penicillin such as procaine and 
bezathine were synthesized and used for intramuscular injection due to their poor 
solubility in water. 
 
The reactive b-lactam ring containing in this group of antibiotics made them unstable and 
very labile. Therefore, a variety of modifications on the nucleus led to changes in their 
chemical properties such as increasing stability in acidic and basic media, lower 
degradation by enzymes and a broader spectrum of activity [9]. 
Pencillinc acid in (Figure 1.4a) shows the core structure of penicillin which upon 
conversion to its Na
+
 or K
+
 salts provides soluble compounds and upon substitution with 
benzathine gives insoluble agent as mentioned earlier. 
The more important modifications in this structure occur on the R group; because the β-
lactam ring reactivity and stability depend on the side chain substitution. This is essential 
for the action of β-lactam antibiotics to act as anti-bacterial agents. 
The first semisynthetic modification was changing the side chain R in penicillin G with 
other side chains. For example, phenoxyethyl, phenoxymethyl, where the  β-lactam ring 
is less reactive to H
+
 due to the change of the electron distribution and a creation of more 
stable entities.    
Figure 1.4B shows the basic chemical structure of cephalosporin which has a basic 
structure as penicillin, but it has six-member dihydrothiazine ring instead of the 
thiazolidine ring in penicillin. Both R1 and R2 provide opportunity for essential side 
chains modifications which result in changes of many properties of the compounds. 
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(A) Penicillin 
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(B) Cephalosporin 
Figure (1.4): Penicillin’s and cephalosporin’s core structure, where the R groups are the 
variable [1]. 
The main entity contained in both structures shown in Figure1. 4 essential for the 
antibacterial activity is the β-lactam ring (Figure. 1.5). This entity interacts with active 
sites in the bacteria and produces the desired antibacterial effect. This happens when  C—
N bond in the β-lactam opens and binds to a carbon atom in the bacteria’s site of action 
by covalent bond, resulting in acylation of an important group needed for cell wall 
synthesis [1]. 
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Figure (1.5): Beta-lactam ring 
 
1.1.1 Mechanism of Action 
 
Cell wall in bacteria is an important structure in both Gram positive and Gram 
negative bacteria because of stress bearing and shape maintaining function [10]. It is a 
complicated structure which is composed of multiple types of polymers, peptidoglycans, 
teichoice acid and lipopolysaccharides. However, the most important among these is 
peptidoglycan because  it is essential for cells living under normal growth conditions. 
Transpeptidase enzyme interacts with the peptide linkage contained in the pentapeptide 
chain of the uncrossed linked peptidoglycan (terminal D-alanine). This interaction results 
in D –alanine release and an acyl enzyme intermediate formation. 
Penicillin behaves like terminal D-alanine in the pentapeptide chain. The CO-N bond in 
β-lactam structure crosses bond to the peptide bond during trans-peptidation. Thus new 
transition state is formed and peptide bond is cleaved; when the enzyme cleaves the β-
lactam ring it forms a stable pencicilloyl-enzyme complex resulting in an inhibition of the 
transpeptidase enzyme (Figure1.6) [11] . Sequence analysis of the peptides derived from 
active site-labelled enzymes has established that both penicilloyl and an acyl moiety 
derived from substrate are covalently bound to the same site, as an ester of serine 36.[12] 
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Figure (1.6): Proposed mechanism of transpeptidation  
 
1.1.1 Development of Amoxicillin 
 
 
In 1972 Amoxicillin was  prepared in the UK, which has the same activity  as 
ampicillin, but with higher bioavailability [13]. Later a combination of amoxicillin with 
clavulanic acid was developed to introduce oral bioavailability and broad spectrum 
activity against a variety of pathogens that produce β-lactamase enzyme [14]. 
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      As mentioned earlier, penicillin contains β-lactam ring which is important for activity 
and mechanism of action. On the other hand, it is sensitive and labile structure in 
presence of basic or acidic media and also can be inactivated by β-lactamases enzymes. 
However, an addition of an amide group to the 6-position in β-lactam  ring can make the 
compound more stable in acidic conditions, due to the fact that the amide oxygen 
becomes  less nucleophilic compared to that  in amoxicillin [15]. 
In 1950, β-lactam group was limited for two drugs with low spectrum of activity, 
penicillin V and penicillin G. As a result, scientists in the field have had interest to 
introduce new compounds of penicillin by a fermentation process, however, this way 
gave limited diversity of compounds [13]. 
Later in 1957, 6-aminopenicillanic was used as a precursor to synthesize new beta 
lactams; and in 1960 stable methicillin was produced. Then the synthesis continued until 
the discovery of broader spectrum penicillin, ampicillin. In 1970 amoxicillin was made 
with better bioavailability than ampicillin [15]. 
 
1.1.5.1 pharmacology  and Pharmacokinetics 
 
     As amoxicillin acts on cell wall of bacteria; it has bactericidal action against both 
gram positive and gram negative. Amoxicillin is used for many indications; treatment 
middle ear infection [15] laryngitis, bronchitis, pneumonia [16], and typhoid fever [15]. 
Amoxicillin is the most commonly  prescribed antibiotic for children, it is well absorbed 
after oral administration, used for treatment in a variety of infections not only for broad 
spectrum also for outstanding advantage  in comparison to other penicillin with higher 
bioavailability of 70-90%, and reaches Cmax within 1-2hours [15]. Amoxicillin is widely 
distributed in the body and the apparent volume of distribution  is 0.26 - 0.31ml/kg, it has 
half-life 1-1.5 hours[17]. Also it is excreted by the renal route and approximately 10-25%  
of  the drug is bio-transformed  into pencillinc acid [15]. 
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1.1.1 Cephalosporin 
 
Cephalosporins are related to penicillin β-lactam antibiotics; they act on cell wall 
of bacteria; interfering and lysing bacterial cell wall. This action is achieved by drug’s 
crossing  and binding to penicillin binding protein in the cell wall (site of action) [18]. 
Cephalosporin has no activity against enterococcus due to low affinity on penicillin 
binding protein. However, it has different activities against Pseudomonas aeruginosa and  
Enterobacteriacea,  because of differences in binding on the active site located on the 
bacteria’s cell wall [19]. 
 Structure activity relationship and differences in side chain substitution at C7 position of 
the main core of cephalosporins led to a various pharmacokinetics properties, spectra of 
activity, and β-lactamase stability (Figure1. 4 b). 
Alteration of the substituent on C7  by the addition of methoxy group (cephamycin) or 
replacing the sulfur in dihydrothiazine ring with oxygen (moxalactam) led to increase 
stability against enzymatic hydrolysis by β-lactamase [18]. 
 
1.2 Research problem   
 
 
1.2.1 Stability 
 
  Conventional oral suspensions and solutions of antibiotics dispensed as powders 
need to be reconstituted with water at the time of use. Reconstitution  process is 
formulation of choice for compounds with low stability; this reconstitution  system 
allows acceptable but short life with storage in refrigerator [20]. The highly strain β–
lactam ring that present in both penicillin and cephalosporin structures is unstable in 
solution; hydrolysis occur and as a result loss of activity.  
So, when the side chain have been altered one can change the activity and 
physiochemical properties such as stability [9]. 
 12 
 
The degradation process is an irreversible chemical change in organic molecular 
structure [21]. The degradation of penicillin can occur in different conditions; acidic or 
alkaline, in presence of weak nucleophile as water and β-lactamase enzyme. 
 
1.2.2 Bitter taste 
 
The palatability of the active ingredient of a drug is a significant obstacle in 
developing a patient friendly dosage form. Organoleptic properties such as taste are an 
important factor when selecting a certain drug from the generic products available in the 
market that have the same active ingredient. It is a key issue for doctors and pharmacists 
administering the drugs particularly for pediatrics and geriatrics [22]. 
The problem of the bitter taste of drugs in pediatric and geriatric formulations still 
creates a challenge to pharmacists. Thus, different strategies should be developed in order 
to overcome this serious problem. The novel chemical approach to be discussed in this 
thesis involves the design of prodrugs for masking bitter taste of pharmaceuticals based 
on intramolecular processes using Density Functional Theory (DFT) methods [23]. No 
enzyme is needed to catalyze the intra-conversion of a prodrug to its corresponding drug. 
The rate of drug release is controlled by the nature of the linker bound to the drug. Bitter 
tasting molecules interact with taste receptors on the tongue to give bitter sensation. 
Altering the ability of the drug to interact with bitter taste receptors could reduce or 
eliminate its bitterness. This could be achieved by an appropriate modification of the 
structure and the size of the bitter compound [24]. 
 
Based on DFT calculations and experimental values obtained from intramolecular acid 
catalyzed hydrolysis in nine maleamic acid, Karaman’s group designed and synthesized 
two pure  prodrugs of amoxicillin and cephalexin by linking these two antibiotics with a 
maleic anhydride linker in order to: (1) improve the stability and aqueous solubility of the 
parent drug (2)  provide drugs without bitter taste.[25]  
The two synthesized prodrugs were designed such that the amine group in the parent 
drug converts to its corresponding amide. Thus, the prodrugs are expected to be more 
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stable than their corresponding amino parent drugs (Figure 1.7). The current thesis is 
devoted to study the antimicrobial activity of the two synthesized prodrugs. 
 
 
 
 
 
 
Figure (1.7): Chemical structures for the proposed prodrugs of Amoxicillin and 
Cephalexin[25] 
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1.3 Research objectives 
 
 
1.3.1 General Objective 
 
 To assess the antibacterial spectrum of two novel prodrugs of amoxicillin, and 
cephalexin 
 
1.3.2 Specific objectives  
 
  To compare activity of prodrugs with their parent compounds. 
  To determine the minimum inhibitory concentration (MIC) and (MBC) of 
the prodrugs. 
 
1.4 Research Questions 
 
1. Do the two synthesized prodrugs possess anti-bacterial activity? 
2. What is the antibacterial activity of the prodrugs relative to their parent drugs?  
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Chapter Two 
Literature Review 
 
 
2.1 History of prodrug research 
 
In 1958 Albert introduced the term prodrug in his article in nature: avail a 
pharmacological inactive moiety that can be used to change a drug's physiochemical 
properties. Later, Harper has built on this concept but the term he used is drug 
latentiation. 
The use of the term generally applied when a drug is linked to chemical moiety by 
covalent bond and the cleavage to release the parent drug can be achieved by chemical or 
enzymatic mean. 
Prodrug is designed to be utilized through a chemical approach, thus it is an alternative 
and short cut of redesigning drug molecules [26-29]. 
Prodrug approach can be utilized to: 
1. Increase solubility and bioavailability of an active drug   
2. Improve permeability and in turn increase drug’s absorption    
3. Modify the drug’s distribution profile [30-33]. 
According to Albert s definition “a prodrug is inactive form of its parent  drug” [29]. But 
there are few prodrugs that have activity before their conversion via enzymatic or 
chemical processes to their parent drugs [34]. 
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2.1.1 Earlier Examples of Prodrugs 
 
In 1899 aspirin was introduced  as less irritating form of sodium salicylate [35],  and 
methenamine which discovered by Shering to give its parent drug, formaldehyde, which 
acts as antibacterial agent for urinary tract infection [36]. 
Prontosil was discovered in 1935 as the first sulfa drug and a prodrug of sulfanilamide 
which ushered in the era of sulfonamide antibiotics. [37]. 
Acetanilide and phenacetin were originally not designed as prodrugs, however   their 
nature as prodrugs was determined  later; acetanilide  exhibited its activity as a result of 
its metabolite  acetaminophen, and phenacetin due to the fact that upon metabolism it 
undergoes o-dealkylation to acetaminophen. Therefore, the nature of these drugs being 
prodrugs was determined in hindsight. Other hindsight examples include phenylbutazone 
metabolized to oxymethylbutazone, primadone to phenobarbitone, codeine to morphine. 
In these examples both the prodrug and its parent drug have pharmacological  activity 
[34]. 
Albert mentioned in his "selective toxicity book”, I apologize for having invented the 
term prodrug, now too widely used to alter, for literary purists tell me they would have 
preferred ‘predrug’  [33] . 
Albert essentially affords the prodrug concept legitimacy as a tool in drug discovery and 
development. 
A number of novel prodrugs that were designed based on enzyme models were studied 
by Karaman's group, among those are aza-nucleoside derivatives for the treatment of 
myelodysplastic syndrome,  paracetamol as a pain killer, anti-malarial atovaquone, anti-
Parkinson dopamine, anti-viral acyclovir, antihypertensive atenolol, antibacterial 
cefuroxime, anti-psoriasis monomethyl maleate, and phenylephrine as decongestant. In 
vitro kinetic studies in a wide pH range have shown promising results for obtaining novel 
prodrugs that may have enhanced dissolution, membrane penetration, and thus better 
bioavailability than their corresponding parent drugs. In conclusion, based on the 
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examples discussed, precise terminology can be drawn as follows: inactive prodrugs 
should be named predrugs and active prodrugs should be named drug-predrugs [34]. 
2.2.1 Antimicrobial Susceptibility Test (AST) 
 
The importance to know whether a microorganism is responding to antibiotics therapy 
is old as chemotherapy itself [38]. 
With an increase in the use of traditional antimicrobial agents, bacterial resistance 
emerged, it has created a problem for clinicians to select suitable antimicrobial agent 
[39], so in vitro antimicrobial susceptibility test should be used for relevant bacterial 
pathogens [40]. 
The aim of in vitro (AST) is to give dependable predictor of how the pathogen responds 
to the chemotherapy in infected host, this important data provide the clinicians the tool to 
pick out the suitable antimicrobial therapy, helps in developing antimicrobial usage 
policy  and supply information for epidemiological surveillance [38]. 
In  1920 Fleming made  two important contributions on AST methods; in 1924 he 
introduced the use  of the dish plate for estimating  antimicrobial qualities of antiseptic 
solution [41].  Broth dilution method utilizing was Fleming’s second contribution by 
which the use of turbidity as end point determination [42]. Later he developed this 
method  by using pH as an indicator instead of turbidity [43] . 
Diffusion technique  of AST  was introduced in 1940, absorbent paper containing 
antimicrobial agents  introduced by Heatley [44], and Vincent introduce filter  paper discs 
incorporating penicillin [45] . 
Mohs  utilized “radial streak disc method,  where the disks has diameter 15 mm, this 
was the first procedure of a comparison of test organism in the same plate with test 
control [46]. 
In 1940, agar dilution AST method was developed by Schmitt Reymann. This method 
is done by incorporating antimicrobial agent into agar plates[42]. 
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In 1950, everyone has realized that it is important to standardize AST measurement; 
consequently many organizations began addressing this important need. The world health 
organization  set a report  on standardization of AST methodology [47].  
In 1966, a significant development happened with the introduction of standardization of 
disk method which was done after Bauer, Kirby and co-workers published their attempt 
to set the disk diffusion method as practical technique of testing with broad application to 
clinical laboratories [48]. This method became the basis of the national committee for 
clinical laboratory standard  (NCCLS), disk diffusion standard [42]. 
2.2.2. Antimicrobial Susceptibility Testing Methods  
2.2.2.1 Disk Diffusion Method 
The disc diffusion method  is simple, practical, qualification test, that is well 
standardized [49].The test is done by bacterial inoculums of 1-2 × 10
8
 cfu/ml.to 
the mullar- Hinton agar plate, then paper antibiotic disks or strips with fixed 
concentration are placed on the inoculated agar surface. After plates incubation at 
35°C for 16-18 hours the results are determined by reading and recording the zone 
of growth inhibition using the ruler. The diameter of the zone is related to the 
diffusion rate of the drug and to the susceptibility of organism [50] (Figure2.1). 
The advantages of this method are the flexibility and test simplicity which does 
not require any special equipment. In addition, it is the least costly among 
susceptibility methods. 
The disadvantages include that not all types of bacteria which has slow growth 
rate can be accurately tested using this method, and for some bacteria there is a 
need to use specialized media or incubation conditions for testing (e.g. 
Neisseria.meningitidis, Hemophilas influenza).  In addition, no automation in this 
test is possible [49]. 
 
 
 20 
 
 
 
 
 
 
                                                                                                    
Figure (2.1): The antimicrobial susceptibility disk diffusion test: approximate disk 
placement and measurement of inhibition zone diameters. 
 
 
2.2.2.2 Broth and Agar Dilution Method 
 
The purpose of the broth and agar dilutions test is to set the lowest concentration 
of the assayed antimicrobial that inhibits the growth of tested bacterium and also 
to get quantitation result. 
The MIC is a result of the lowest test concentration that inhibits the bacterium; 
however, it can be between that concentration and the next lower one.  Hence, 
MIC does not always appear as an absolute estimate.[51] 
 
 
2.2.2.2.1 Broth Dilution 
The tube dilution method is one of the earliest antimicrobial susceptibility  
testing method; its technique performed by suspension of bacterium (which 
previously determined optimal concentration) is tested against different 
concentrations of an antimicrobial compound. 
Antibiotic disk 
Growth 
1
1 
 Inhibition 
zone 
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This method can be done either in tubes containing 2 ml as minimum volume 
(macro-dilution) or (micro-dilution) using micro-titration (Figure 2.2). 
 
 
 
Figure (2.2): A broth micro dilution susceptibility panel containing 98 reagent wells and 
disposable tray inoculators. 
 
 
The tubes containing antibiotics are inoculated with bacterial suspension and incubated at 
35°C.  After overnight incubation the tubes are tested to determine the MIC by visible 
bacterial growth estimated by turbidity. The lowest concentration that inhibits the growth 
of bacterial appears as minimum inhibitory concentration. 
The advantages of this method is that it gives quantitative result [52].  In addition, the 
same tubes can be taken for minimum bactericidal  concentration assay [51]. 
The disadvantages of this method; it is not simple since there is a need for preparing the 
antibiotic solutions for each test and errors may occur during preparation. Furthermore, it 
is costly and less flexible than the disk method. 
 
2.2.2. 2.2 Agar Dilution 
 
Agar dilution is performed by incorporation of different concentrations usually two folds 
of the antimicrobial agent into an agar plate; then the defined bacterial inoculum is 
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applied to the agar surface. Agar dilution test is recommended as standardized  AST  
method for  fastidious organisms [52]. 
 
2.2.2.3 E Test 
 
The E_test is an in vitro procedure developed to set minimum inhibitory concentration of 
an antimicrobial compound on agar medium; the E_test avoids some disadvantages of the 
disk and broth methods. In addition, it simply gives quantitative MIC. 
The E_ test consists of continuous concentration gradient of stabilized and dried drug that 
carried on a thin reagent strips; the E_test performed by swab the inoculated bacteria on 
an agar plate as the same principle in agar diffusion test; then one or more E_test strips of 
the antimicrobial compound to be tested are placed on the agar surface. Following an 
overnight incubation, the results appear as elliptical inhibitory zone (Figure 2.3) [53]. 
 
 
 
 
 
Figure (2.3): The minimum inhibitory concentration of each agent is determined by the 
intersection of the organism growth with the strip as measured using the scale inscribed 
on the strip [49]. 
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2.2.2.4 Automated Instrument System  
 
Use of instrument produces susceptibility test  results in a short period and standardizing 
the reading of end points; its optical sensitive detection system which can detect changes 
in bacterial growth; the instrument incubates the trays over a period of time, testing them 
periodically  with either fluorometric  or photometer to examine a growth development 
[49]. 
 
2.3 Minimum Bactericidal Concentrations (MBC) 
 
As mentioned previously the advantage of using the broth dilution method for MIC set is 
the ability to use the same tubes and continue working to determine MBC.[51] 
  
 
2.4 Antimicrobial Activity of Amoxicillin and Cephalexin  
2.4.1 Amoxicillin Activity 
Penicillins have been divided into classes based on their spectrum of activity; the first 
agent that was used clinically to treat infections is the natural penicillin (penicillin G), but 
after the emergence of penicillinase in staphylococci penicillins became inefficient for 
these organisms. Therefore, development of penicillinase resistant-penicillins was 
initiated; this led to the development of three categories of penicillins: the 
aminopenicillins, carboxypencillins and ureidopencillin [54]. 
 
Aminopenicillins was the first class of penicillin antibiotic that has activity to both gram 
positive and gram negative bacteria; ampicillin compared to natural penicillin has more 
activity against enterococci, but somewhat less activity against pyogens, streptococcus 
pneumonia, and Neisseria species. On the other hand, it has some activity against E.coli, 
proteus Mirabella,  salmonella, shigella, listeria, which are gram negative bacteria [54]. 
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Amoxicillin has shown to be effective against a variety of infections, which are caused by 
gram positive and gram negative bacteria in humans and in animals [55]. Amoxicillin has 
a higher activity against gram positive than gram negative microorganisms [56]. In 
addition,  it has greater efficacy relative to penicillinV and other antimicrobial such as 
ampicillin [15] and cefuroxime [57]. 
 Different study reports showed that amoxicillin was effective at MIC ranges 0.06 μg/ml -
4 μg/ml against variety of microorganism, except staphylococcus .epi 64 μg/ml and 
staphylococcus aureus  MIC up to 256 μg/ml [58]. 
 
In a study, amoxicillin and ampicillin showed that the kill rates for amoxicillin was 
higher than ampicillin for E.coli, and the rate of killing was the same for both agents for  
Staphylococcus Aureus, but amoxicillin showed longer bacteriostatic  phase which was 
not observed with ampicillin [15]. 
In another study an investigation on the antibacterial activity of amoxicillin and 
ampicillin against 30 isolates of each proteus mirabilis, Klebsiella, E.coli, Enterobacter 
and idol positive proteus was carried out, and the results obtained are as follows:  
89% of the strains of E.coli was inhibited by both drugs at 10 μg or less per ml, and at 5.  
    μg or less    Proteus.mirabilas was inhibited by both drugs.  
On other hand, high response of resistance to amoxicillin and ampicillin was seen among 
strains of klebselia, enterobacter and idol positive species [59]. 
 
In addition, other studies showed that amoxicillin was especially active against group A 
hemolytic streptococci, penicillin G susceptible staphylococcus aureus and pneumococci  
only 28% of S. aureus  isolates which were resistant to 50 μg of penicillin G per ml were 
susceptible at 50 μg/ml or less  to amoxicillin,  76% of p.mirabilas isolates were 
susceptible to amoxicillin at 1.56 μg/ml or less and 20% showed resistant to 12.5 μg/ml 
or more,  75% of E.coli isolates were susceptible to 6.65 μg/ml or less and most of the 
remaining isolates were resistant to 50 μg/ml or more [60]. 
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2.4.2 Cephalexin Activity 
 
First generation cephalosporins are cefazolin, cephapirin and cephalothin for 
intravenous use and cephalexin, cephradine, and cefadroxil which are used orally.  All of 
these cephalosporins are similar in spectrum of activity. They have high activity against 
gram-positive cocci. They have low activity against gram negative bacteria. In addition, 
most strains of Escherichia coli, Klebsiella species, and Proteus mirabilis are sensitive to 
this class of drugs. They have no activity against methicillin-resistant Staphylococcus 
aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE), as well as 
enterococci, Listeria monocytogenes, Bacteroides fragilis, Citrobacter, Enterobacter, 
Proteus (other than mirabilis), Providencia, Pseudomonas, and Serratia organisms. 
Gram-positive anaerobes like Peptostreptococcus and non-penicillinase producing 
Bacteroides species are usually sensitive [18]. 
Cephalexin is used for the treatment of the upper and lower respiratory tract infections, 
genitourinary system, skin, soft tissue, bones, joints and many other infections due to 
susceptible organisms [61]. 
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Chapter Three 
 
Experimental Part 
 
3.1. Media Preparation 
Brain heart infusion agar, Muller Hinton agar (Becton ,Disckinsonand company sparks 
USA)and nutrient broth(hemedia laboratories pvt.ltd) were prepared in concentrations of 
52 gm/L, 38 gm/L and 13 gm/L, respectively. 
3.2. Preparation of the Buffer Solution 
Buffer solution (pH=7.4) was prepared by dissolving 0.68 gm of potassium dihydrogen 
phosphate in100 ml water, then NaOH was added and the solution was stirred.( pH meter 
model HM-30G: TOA electronics™ was used to measure the pH value for all buffers and 
reaction media involved in this study.) 
 
 
3.3 Test Microorganisms 
Reference strains obtained from American Type Culture Collection (ATCC) were used 
(Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), 
Escherichia coli (ATCC 25922), Klebsiella pneumonia (ATCC 700603), 
Streptococcuspyogens (ATCC 19615), and Streptococcus group B obtained from 
microbiological labs (Al-Quds University). 
3.3.1Preparation of Inocula 
 
Part of an isolated bacterial colony was inoculated in 5 ml nutrient broth & incubated for 
24 hours at 37
o
C, the growth turbidity in nutrient broth was adjusted by further incubation 
or dilution with sterile physiological saline; after comparison with that of a McFarland 
nephlometer tube no. 0.5 (10
8
cfu/ml) using spectrophotometer at 625 nm (optical density 
of 0.08-0.1) 
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3.4 Antimicrobial Activity Screening Methods 
3.4.1 Disk Diffusion Method  
With a sterile cotton applicator 10
8
cfu/ml of each bacterial strain was swabbed on Muller 
Hinton agar (for Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, 
and Klebsiella pneumonia) while brain heart infusion agar was used for Streptococci spp. 
in the following manner 
1. The cotton applicator was dipped into the bacterial suspension, rotated several 
times and pressed against the inside wall of the tube to remove excess 
inoculum. 
2. The agar plate was then streaked in three different directions and around the agar 
margin to ensure even distribution of the inoculum. 
3. The plates were left to dry for 3-5 minutes. 
4. Using sterile forceps the disks, which contain prodrugs, drugs, negative control 
were then distributed evenly on the surface of the agar plates. 
5. The plates were incubated upside-down at 37 oC.  
6. The inhibition zone around each disk was measured using a transparent ruler. 
3.4.2 Broth Dilution Method  
 
3.4.2.1 Preparation of Media 
For each strain 13 tubes, each contains 9.9 ml Muller Hinton broth were prepared and 
autoclaved. 
3.4.2.2 Preparation of the Active Ingredient Dilutions 
Two main prodrugs of amoxicillin and cephalexin along with their parent drugs ( Pure 
standards (>99%) of amoxicillin and cephalexin were available commercially from 
Sigma Aldrich  & cephalexin), as positive control were used. 500 mg of each drug and 
prodrug were dissolved in 10 ml of buffer solution pH 7.4, that has no effect on tested 
microorganisms and the prodrugs have maximum stability[25], to give a final 
concentration of 50 mg/ml. Then several dilutions of stock solution were prepared as 
shown in Table 3.1.[62] 
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Table 3.1: Dilutions of active ingredients  
 
Tube 
no. 
Stock solution 
50 mg/ml 
Buffer 
(mL) 
Final 
concentration 
mg/ml 
Volume 
of broth  
Final volume 
added to each 
tube 
1 1 ml 0 50 9.7 ml 0.3 ml 
2 1 ml 0 50 9.75 ml 0.25 ml 
3 1 ml 0 50 9.8 ml 0.2 ml 
4 1 ml 0 50 9.9 ml 0.1 ml 
5 0.9 ml 0.1 45 9.9 ml 0.1 ml 
6 0.8 ml 0.2 40 9.9 ml 0.1 ml 
7 0.7 ml 0.3 35 9.9 ml 0.1 ml 
8 0.6 ml 0.4 30 9.9 ml 0.1 ml 
9 0.5 ml 0.5 25 9.9 ml 0.1 ml 
10 0.4 ml 0.6 20 9.9 ml 0.1 ml 
11 0.3 ml 0.7 15 9.9 ml 0.1 ml 
12 0.2 ml 0.8 10 9.9 ml 0.1 ml 
13 0 ml 1 0 9.9 ml 0.1 ml 
 
The experiment was repeated with Klebsiella, which required lower concentrations to 
find MIC and MBC. Broth tubes containing the active ingredients with different 
concentrationswere prepared as shown in the Table 3.2. 
Table 3.2: Dilutions of active ingredients used for klebselia 
Tube no. Stock solution 
50mg/ml 
Buffer (mL) Final 
concentration 
mg/ml 
Final 
concentration 
mg/0.1ml 
1 1  0 50 5 
2 0.9 0.1 45 4.5 
3 0.8 0.2 40 4 
4 0.7 0.3 35 3.5 
5 0.6 0.4 30 3 
6 0.5 0.5 25 2.5 
7 0.4 0.6 20 2 
8 0.3 0.7 15 1.5 
9 0.2 0.8 10 1 
10 0.1 0.9 5 0.5 
11 0.05 0.95 2.5 0.25 
12 0.025 0.975 1.25 0.125 
13 0 1 0 0 
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3.4.2.3 Incorporation of Active Ingredients into Media 
For the incorporation of  the active ingredients  into media, 13 broth tubes each contains 
broth volume as shown in Table 3.1 in to broth tube 1, 300 microliter (0.3 ml) of stock 
solution was added into broth tube 2, 250 microliter was added and 200 microliter into 
broth tube 3. 
The procedure was repeated for the remaining dilutions by adding 100 microliter (0.1 ml) 
for each tube, the final concentrations of the active ingredients in broth are shown in 
Tables 3.3 and 3.4. 
Table (3.3): Final concentration of the active ingredients,amoxicillin 
,cephalexin(drug and prodrug) in the medium. Against  staphylococcus aureus, 
Staphylococcus epidermidis Escherichia coli , Streptococcus pyogens group A, and 
Streptococcus group B 
Tube no. 1 2 3 4 5 6 7 8 9 10 11 12 
Concentration  
microgram/ml 
150 125 100 50 45 40 35 30 25 20 15 10 
 
Table (3.4): Final concentration of the active ingredients amoxicillin 
,cephalexin(drug and prodrug) used for Klebsiella 
Tube no. 1 2 3 4 5 6 7 8 9 10 11 12 
Concentration  
microgram/ml 
50 45 40 35 30 25 20 15 10 5 2.5 1.25 
 
3.4.2.4 Determination of Minimum Inhibitory Concentration (MIC) 
All tubes were inoculated with 10 µl of the tested bacterial suspension; the tubes were 
then incubated for 24 hours at 37
o
 C. 
After incubation, the tubes were examined for turbidity, indicating a growth of 
microorganisms; the organism will grow in the negative control tube (tube no.13) that 
does not contain antimicrobial agent to inhibit growth. The lowest concentration of the 
prodrug that inhibits a growth of the organism, as detected by a lack of visual turbidity is 
designated as the MIC (Figure 3.1.) 
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Figure (3.1): Broth dilution susceptibility test; the tube number 5 lacks of visual 
turbidity.  
 
MBC is interpreted to be at a tube that shows no growth on the agar plate for example 
Figure 3.1 shows that MIC for the test illustrated in the figure in tube no. 5 is 45 
microgram per ml; while MBC is checked by testing viable colonies in tubes 1-5.  
Therefore, after reading the results of MIC by recording the lowest concentration that 
inhibits the organism growth, the following procedure is followed: 
1. Sub-culturing of all tubes which have no visible growth by spreading loop full 
over quarter of the agar plate. 
2. incubation at 37 °C and  After overnight incubation read the result and record as 
follow: 
 Bacteriostatic if similar number of colonies are present 
 Partial bactericidal if reduced number of colonies are found 
 No growth indicates that the whole inoculums  have been kille[51] 
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Results and Discussion 
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Chapter Four 
 
Results and Discussion part 
 
 
4.1 Screening of drug an prodrug inhibition of bacteria showing zone 
of inhibition diameter in mm (Table 4.1 and Figures 4.1-4.2) 
 
 
 
Table 4.1: drug and prodrug inhibition of bacteria showing zone of inhibition 
diameter in (mm) 
Amoxicillin drug and prodrug(P value =.141) 
Cephalexin drug and prodrug( p value=.003) 
 
 
Drugs and 
prodrugs 
Staph. 
Epidermidis 
(G+) 
Staph. 
aureus 
(G+) 
Streptoc
occi. B 
(G+) 
Streptoco
cci. A 
(G+) 
klebselia 
 
(G-ve) 
E. coli 
 
(G-ve) 
Amoxicillin 
 
no inhibition 
zone  
44 mm 30 mm 40 mm no inhibition 
zone  
33 mm 
 
 
Amoxicillin 
prodrug 
 
no inhibition 
zone  
30 mm 30 mm 26 mm no inhibition 
zone  
31mm 
 
 
Cephalexin 
 
25 mm 44 mm 33 mm 37 mm 26 mm 29 mm 
Cephalexin 
Prodrug 
 
20 mm 40 mm 32 mm 30 mm 21 mm 24 mm 
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Figure (4.1): antibacterial activity of drug and prodrug of amoxicillin against bacterial 
strain. 
 
 
Figure (4.2): antibacterial activity of drug and prodrug of cephalexin against bacterial 
strain. 
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Figure (4.3). Percentage of prodrug to drug of amoxicillin against bacteria. 
 
 
Figure (4.4): Percentage of prodrug to drug of cephalexin against bacteria. 
  
 
Chemical modification on the reactive β–lactam ring can change the chemical properties 
and spectrum of activity of a certain antibacterial agent. Novel amoxicillin and 
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cephalexin prodrugs were designed and synthesized by karaman's group. The prodrugs 
design was accomplished using DFT calculations. 
The goal of the present work was to study the antibacterial spectrum of these two new 
prodrugs since the β-lactam ring still present, which is needed for the antibacterial 
activity.  
The results shown in Table 4.1 revealed that the novel two prodrugs have antibacterial 
activity on most bacterial strains studied with about the same potency as their parent 
drugs for  amoxicillin. And its not significantly difference (p value =.141) 
Klebsiella showed resistance to amoxicillin drug and its prodrug since  klesiellais is a 
gram negative bacteria, which exhibits resistance to amoxicillin drug [59], and there is a 
need of clavulanic acid to overcome its resistance. 
Staphylococcus epidermidis also showed resistance to amoxicillin drug and its prodrug 
since it is β -lactamase positive. Cephalexin drug and its prodrug showed inhibition 
against all bacterial strains used including Klebsiella pneumonia and E.coli, since 
cephalexin drug has broader spectrum than amoxicillin (Table 4.1) 
In addition, the results showed the percentage sensitivity of prodrug to drug against 
bacterial strains used in this work. For amoxicillin, 94% against E.coli, 59% against strep. 
A, 100% against strep. B and 68% against staph. arues. (Figure 4.3). For cephalexin the 
percentage of prodrug to drug is 82% against E.coli, 80% klebselia, 96% streptococcus 
group. B, 81% strep. A, 81% staphylococcus. Epidermidiss and 91% for staphylococcus. 
areus (Figure 4.4). 
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Figure (4.5): Zone of inhibition in mm determined for each agent against staphylococcus 
epidermidis: (1) amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin drug, (4) 
cephalexin prodrug and (5) negative control (buffer) 
 
 
Figure (4.6): Zone of inhibition in mm determined for each agent against E .coli: (1) 
amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin drug, (4) cephalexin prodrug 
and (5) negative control (buffer) 
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Figure (4.7): Zone of inhibition in mm determined for each agents against 
staphylococcus aureus: (1) amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin 
drug, (4) cephalexin prodrug and (5) negative control (buffer) 
 
Figure (4.8): Zone of inhibition in mm determined for each agent against streptococcus 
group B: (1) amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin drug, (4) 
cephalexin prodrug and (5) negative control (buffer) 
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Figure (4.9): Zone of inhibition in mm determined for each agent against Klebsiella: (1) 
amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin drug, (4) cephalexin prodrug 
and (5) negative control (buffer) 
 
Figure (4.10): Zone of inhibition determined for each agent against streptococcus group 
A: (1) amoxicillin drug, (2) amoxicillin prodrug, (3) cephalexin drug, (4) cephalexin 
prodrug and (5) negative control (buffer). 
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4.2 MIC and MBC result in microgram/ml     
   Table (4.2): MIC, MBC of (amoxicillin, cephalexin) drug and prodrug 
Atcc bacteria Amoxicillin drug Amoxicillin prodrug 
MIC MBC MIC MBC 
Streptococcus. Group B 100 100 >150 >150 
E-coli 10 10 10 10 
Staphylococcus. areus  
50 
 
100 
>150 >150 
Staphylococcus. Epidemidis --- ---- ---- ---- 
klebseilla ----- ---- ---- ---- 
Streptococcus . group A 45 100 >150 >150 
 
 
    
     
cphalexin drug and prodrug MIC(p value =.004) ,cphalexin drug and prodrugMBC(pvalue 
=.098) 
 
In this study the MIC and MBC values for both amoxicillin and cephalexin prodrugs 
were determined and compared with the values of their parent drugs.  
Atcc bacteria Cephalexin drug Cephalexin 
prodrug 
MIC MBC MIC MBC 
Streptococcus. Group B 45 50 50 100 
E-coli 10 10 15 20 
Staphylococcus. areus 35 
 
40 35 40 
Staphylococcus 
.epidermidis 
45 125 50 150 
Klebsiella 5 5 10 15 
Streptococcus.Group A 
 
 
45 
 
100 
 
50 
 
100 
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Amoxicillin parent drug against strep. B, staph arues, strep. A was more potent than its 
prodrug since lower concentrations of drug are needed to inhibit and kill bacteria. 
Amoxicillin parent drug has the same MIC value as the prodrug against E.coli 10ug/ml 
this finding is similar to previous studies.[59, 63]   This means that they are equal in 
potency.as they have the same MIC and MBC results.  
Amoxicillin drug has different MIC value than the prodrug against sstaphylococcus. 
areues for the parent drug the MIC value was 50 ug/ml which is similar to that reported in 
previous studies.[60] 
All results that are above 150 ug/ml need higher concentration to determine the exact 
value since 150 microgram is the maximum concentration used in this work (Table 4.3). 
Cephalexin parent drug was slightly more potent than the prodrug, because the MIC and 
MBC values of the parent drug were not significantly (p value = 0.98) lower than that of 
the prodrug. Table 4.4 indicates that the prodrug of cephalexin was more potent than the 
prodrug of amoxicillin; since all MIC and MBC measured values for cephalexin prodrug 
were less or equal to 150 ug/ml. 
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Conclusions and Future directions 
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Conclusion and Future directions 
Chapter five 
 
1.1 Conclusion  
 
The two synthesized prodrugs of amoxicillin and cephalexin were designed such that the 
amine group in the parent drug is replaced with its corresponding amide. Thus, both 
prodrugs are expected to be more stable than their corresponding parent drugs, 
amoxicillin and cephalexin.  
It is worth noting that those two novel prodrugs are among a small number of prodrugs 
that have activity themselves before undergoing conversion via enzymatic or chemical 
processes to their corresponding parent drugs. The novel prodrugs exhibit their 
antibacterial activity against different types of bacterial strains due to the presence of beta 
lactam ring in their structures.  
 
5.1  Future direction  
The steps to be taken in the future will include the followings: 
(1) A determination of the exact MIC, MBC for those results having values above 150 
ug/ml. 
(2)  An assessment of the antibacterial activity on other types of bacteria in addition to 
those used in this work. 
(3) In vivo testing of the novel prodrugs in the absence and presence of clavulanic acid.  
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 الملخص
 
 
وليّْين جديدْين مبتكرْين لدوائْين أنات الدقيقه  ئدراسىة الفعالية المضادة للكا
 من مضادات البكتيريا؛ الأموكسيلين والسيفالكسين
 .
 
 
دوائْين أوليّْين جديدْين مبتكرْين من مضادات البكتيريا؛ الأموكسيلين  تم تصميم وتركيبلقد 
 . المذاق المّر وقلة الثباتلتحسين  sgurdorp((والسيفالكسين
  ضدت الدقيقه  نائلقد تم دراسة الفعالية المضادة للكا
 suerua succocolyhpats ,sidimredipe succocolyhpats ,iloc aihcirehcsE
 ,B puorg succocotperts ,A puorg succocotperts ,ainomuenp alleisbelK
لاضافه تم تحديد اقل تركيز من ابsgurd( ( الأموكسيلين والسيفالكسينوقد تم مقارنة الفعاليه مع 
اظهرت , )CBM,CIM(مكن ان يمنع نمو الكائنات الدقيقه او يقضي عليها كليا الماده الفعاله ي
 الاصليين الأموكسيلين والسيفالكسينلفعاليه لهم فعاليه مقاربه  sgurdorp((الدراسه ان الدوائين
 succocolyhpats  ,ainomuenp alleisbelK(فقد كانت ,بلنسبه لأنواع البكتيريا المستخدمه 
فقد كان ) iloc aihcirehcsEا (). gurdorp dna gurd(قاومه للاموكسيلين م) sidimredipe
 .lm/gu01) gurdorp dna gurd( اموكسيليناقل تركيز لتثبيطها لكلا الدوائين 
 dna gurd(لكلا الدوائين ) )CBM,CIM لم يكن هناك فرق كبير في قيم السيفالكسينبلنسبه الى 
 )gurdorp
 
 
